Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups

SIMPLE SUMMARY: Around 2–4% of lung adenocarcinoma harbors BRAF mutations. Dabrafenib and Trametinib represent the first treatment-choice for BRAF V600E(mut) NSCLC, regardless of the line of therapy, while non-V600E(mut) receive standard immunotherapy or chemo-immunotherapy. Our real-life multicente...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Fabiana, Mazzaschi, Giulia, Minari, Roberta, Verzè, Michela, Azzoni, Cinzia, Bottarelli, Lorena, Nizzoli, Rita, Pluchino, Monica, Altimari, Annalisa, Gruppioni, Elisa, Sperandi, Francesca, Andrini, Elisa, Guaitoli, Giorgia, Bertolini, Federica, Barbieri, Fausto, Bettelli, Stefania, Longo, Lucia, Pagano, Maria, Bonelli, Candida, Tagliavini, Elena, Nicoli, Davide, Ubiali, Alessandro, Zangrandi, Adriano, Trubini, Serena, Proietto, Manuela, Gnetti, Letizia, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031288/
https://www.ncbi.nlm.nih.gov/pubmed/35454926
http://dx.doi.org/10.3390/cancers14082019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031288/
https://www.ncbi.nlm.nih.gov/pubmed/35454926
http://dx.doi.org/10.3390/cancers14082019

Ejemplares similares